ADJUVANT, PVAX14 DNA, AS AN IMMUNOTHERAPY FOR A MOUSE MODEL OF HIGH RISK MYELODYSPLASTIC SYNDROME (HR-MDS) EXTENDS SURVIVAL AS ADD-ON TREATMENT TO AZACITIDINE (AZA)
Leukemia Research（2015）
Key words
high risk myelodysplastic syndrome,immunotherapy,azacitidine,adjuvant,hr-mds
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined